HZHaohan Zhu

Haohan Zhu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Haohan Zhu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Peijing Rong

    Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences

    2 shared publications
  • Xingke Song

    Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China

    2 shared publications
  • Chen Xin

    Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China

    1 shared publication
  • Han-Yu Deng

    Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China

    1 shared publication
  • Jian-Liang Zhang

    Department of Physiology, Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing, China

    1 shared publication
  • Jin-Ling Zhang

    Department of Physiology, Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing, China

    1 shared publication

Latest Publications

  • Open Access

    Transcutaneous auricular vagus nerve stimulation alleviates depression-like behavior by rebalancing septohippocampal cholinergic-microglial signaling

    by Haohan Zhu, Yu Chen, Xingke Song, Zijie Chen, Jinling Zhang, Xue Pu, Junying Wang, Peijing Rong

  • Open Access

    NTS Neural Subtypes and Satiety Pathways: taVNS as a Novel Neuromodulatory Intervention

    by Hanyu Deng, Chen Xin, Haohan Zhu, Xinjiang Zhang, Lan Sun, Yanfeng Zheng, Peijing Rong

    The global obesity epidemic has become one of the most severe public health challenges of the 21st century, and existing treatment strategies have limitations such as poor long-term adherence, significant side effects, or high invasiveness. Dysregulation of feeding behavior is the core driver of obesity, and its precise regulation depends on the complete transmission of gut–brain axis signals. The nucleus of the solitary tract (NTS), as the first central relay station for visceral afferent signals, is a key hub for the regulation of feeding homeostasis. This article reviews the peripheral signal transduction mechanisms of hunger and satiety, the core afferent pathway of the vagus nerve, and the functional heterogeneity of neuron subpopulations within the NTS, focusing on the anatomical basis, neuroimaging evidence, and preclinical and clinical research progress of transcutaneous auricular vagus nerve stimulation (taVNS) targeting the NTS to exert anti-obesity effects. Accumulating evidence suggests that taVNS may modulate the activity of satiety-promoting neurons and attenuate aberrant hyperactivity of TH+ catecholaminergic neurons in obesity via the auricular branch of the vagus nerve–NTS pathway, which may in turn bidirectionally suppress homeostatic and hedonic feeding, reduce energy intake, and ameliorate metabolic dysregulation. Current research still has key gaps such as unstandardized stimulation parameters, lack of large-sample long-term randomized controlled trials, and unclear interaction mechanisms between the NTS and higher brain regions. This article provides a theoretical basis for in-depth understanding of the feeding regulatory network of the NTS and the translational application of taVNS in obesity management.

  • Open Access

    Transcutaneous Auricular Vagus Nerve Stimulation Alleviates Headache Symptoms in Migraine Model Mice by the Locus Coeruleus/Noradrenergic System: An Experimental Study in a Mouse Model of Migraine

    by Xingke Song, Zijie Chen, Haohan Zhu, Peijing Rong, Jinling Zhang, Xue Pu, Junying Wang

    Background/Objectives: Migraine is a complex neurological headache disorder, and transcutaneous auricular vagus nerve stimulation (taVNS) can effectively relieve headache symptoms, but its mechanism of effect is still unclear. This study aimed to explore the regulatory effects of taVNS on the locus coeruleus (LC) and the norepinephrine (NE) system in migraine mice. Methods: C57/BL6 mice were randomly assigned to four experimental groups: the control group, model group, taVNS group, and sham taVNS group. A migraine model was established by administration of nitroglycerin. Headache behaviors were assessed using the orofacial stimulation test (OST) and the mouse grimace scale (MGS). Immunofluorescence staining was conducted to evaluate the expression of NE neurons in the LC, while Western blotting was used to determine the expression levels of α-2A adrenergic receptors in the spinal trigeminal nucleus caudalis (Sp5C). Additionally, fiber-optic recording was employed to monitor the real-time dynamics of NE release in Sp5C. Results: After taVNS intervention, the drinking time of OST in the model mice was significantly prolonged(p < 0.05), and facial expression scores were reduced (p < 0.05). TaVNS increased the number of NE neurons in the LC (p < 0.05), promoted the release of NE in Sp5C (p < 0.05), and upregulated the expression of α-2A adrenergic receptors in Sp5C (p < 0.05). Conclusions: The analgesic effects of taVNS are related to the activation of the LC-NE system and the inhibition of the decrease in Sp5C in migraine mice.


  • Involvement of the astroglial glutamate–glutamine cycle in the analgesic effects of electroacupuncture in a rat model of chronic neuropathic pain

    by Hao-Han Zhu, Xing-Ke Song, Jian-Liang Zhang, Jin-Ling Zhang, Pei-Jing Rong, Jun-Ying Wang

    Objective: Our previous study found that astrocytes are involved in cumulative analgesia; however, the underlying mechanism remains unclear. The aim of this study was to further explore the potential role of astrocytes in the effects of electroacupuncture (EA) on neuropathic pain by focusing on the glutamate–glutamine cycle. Methods: 69 male Sprague–Dawley (SD) rats were randomly divided into a normal control group, untreated chronic constriction injury (CCI) model group and EA-treated model (CCI + EA) group. EA was applied bilaterally at ST36 and GB34. Pain thresholds were assessed using behavioral tests and thermal stimuli. We examined the co-expression of glutamate/aspartate transporter (GLAST) via immunofluorescence and measured the expression levels of GLAST, glutamate transporter (GLT)-1 and glutamine synthetase (GS) using Western blotting and polymerase chain reaction (PCR). Glutamate (Glu) and gamma-aminobutyric acid (GABA) levels were detected by high-performance liquid chromatography (HPLC). To validate the impact of GLAST/GLT-1 in the analgesic effect of EA, an additional 30 SD male rats were divided into groups receiving intrathecal saline, GLAST antagonist or GLT-1 antagonist alongside EA. Results: Post-CCI, pain thresholds were decreased, GLAST expression was diminished, and spinal Glu levels were increased. EA treatment reversed these effects, improved pain thresholds and GLAST/GLT-1 expression in astrocytes, and reduced Glu levels. Antagonist administration negated the analgesic effects of EA. Conclusion: Repeated EA administration inhibited CCI-induced chronic neuropathic pain in rats, corresponding to a reversal of decreased expression of GLAST and GLT-1, which may have accelerated the clearance of Glu and thereby reduced its concentration. Regulation of the astroglial glutamate–glutamine cycle is a potential target of EA.